ArticleESMO gastrointestinal oncology2025
Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers.
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal form of cancer with limited treatment options and poor survival rates. Cannabinoids have demonstrated antiproliferative and proapoptotic effects in various cancer types, including PDAC, making them promising therapeutic agents. However, clinical efficacy remains underexplored, particularly for cannabinoids like cannabidiol and tetrahydrocannabinol, which show limited activity against pancreatic cancer. Materials and methods: We synthesized novel cannabinoid analogues, including CCL-106 and its epimers CCL-114 and CCL-115, which exhibit superior antitumor activity in both two-dimensional and three-dimensional pancreatic cancer models. Results: These compounds demonstrated substantially lower concentration that causes 50% inhibition of growth (IC Conclusions: These findings suggest that CCL-106 and its epimers hold potential as effective and less-toxic therapeutic options for PDAC treatment. Further clinical studies are warranted to explore their translational application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.